Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months. - Schnyder Ghamloush S; Fanning S; Essink B; Eder F; Snape MD; Stoszek SK; Guo R; Dhar R; Righi V; Morsy L; Kapoor A; El Asmar L; et al. (Human vaccines & immunotherapeutics, 2025)